M159 M159 (Didanosine Delayed Release 125 mg)
Pill with imprint M159 M159 is White, Capsule-shape and has been identified as Didanosine Delayed Release 125 mg. It is supplied by Mylan Pharmaceuticals Inc.
Didanosine is used in the treatment of nonoccupational exposure; hiv infection and belongs to the drug class nucleoside reverse transcriptase inhibitors (NRTIs). There is no proven risk in humans during pregnancy. Didanosine 125 mg is not a controlled substance under the Controlled Substances Act (CSA).
Images for M159 M159
Didanosine Delayed Release
- Imprint
- M159 M159
- Strength
- 125 mg
- Color
- White
- Size
- 18.00 mm
- Shape
- Capsule-shape
- Availability
- Prescription only
- Drug Class
- Nucleoside reverse transcriptase inhibitors (NRTIs)
- Pregnancy Category
- B - No proven risk in humans
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Mylan Pharmaceuticals Inc.
- National Drug Code (NDC)
- 00378-8886 (Discontinued)
- Inactive Ingredients
-
ferrosoferric oxide,
carboxymethylcellulose sodium,
silicon dioxide,
diethyl phthalate,
gelatin,
hypromelloses,
methacrylic acid - methyl methacrylate copolymer (1:1),
propylene glycol,
shellac,
trisodium citrate dihydrate,
sodium lauryl sulfate,
sodium starch glycolate type A potato,
magnesium silicate,
titanium dioxide,
potassium hydroxide,
ammonia
Note: Inactive ingredients may vary.
Related images for "M159 M159"
More about didanosine
- Side effects
- Drug interactions
- Dosage information
- During pregnancy or Breastfeeding
- Drug images
- En español
- Drug class: nucleoside reverse transcriptase inhibitors (NRTIs)
Patient resources
Other brands
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.